Giredestrant is definitely generating buzz in the breast cancer community! It's an oral selective estrogen receptor degrader (SERD) being studied for hormone receptor (HR)-positive breast cancer. It works by blocking and breaking down estrogen receptors that can fuel cancer growth.
It's currently in clinical trials Show Full Answer
Giredestrant is definitely generating buzz in the breast cancer community! It's an oral selective estrogen receptor degrader (SERD) being studied for hormone receptor (HR)-positive breast cancer. It works by blocking and breaking down estrogen receptors that can fuel cancer growth.
It's currently in clinical trials, including studies for early-stage and advanced HR-positive breast cancer. While it hasn't received FDA approval yet, results so far have been promising enough to keep researchers excited.
Here's what's worth knowing:
- It's being explored as both a standalone treatment and in combination with other therapies
- It's taken as a daily pill, which could be more convenient than some injectable options
- Early trial data has shown encouraging results in slowing cancer progression
- Larger trials are still ongoing to confirm its effectiveness and safety profile
Since it's not yet FDA-approved, it may currently be accessible through clinical trials. It's worth having a conversation with your oncologist to see if a trial might be a good fit for your specific situation. They'll know your full picture best!
June 6
Join
Your Privacy Choices
